Previous 10 | Next 10 |
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...
TryptageniX, a majority-owned joint venture with CB Therapeutics, employs bioprospecting to develop new chemical entities with potential applications in mental health. This new platform company will focus on the generation of intellectual property and further strengthen atai’s ...
Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass Pathways (NASDAQ: CMPS) is a mental health care company that is focused on improvin...
atai Life Sciences (NASDAQ:ATAI) increased its ownership interest in COMPASS Pathways from 19.4% to 20.8% indicating the potential of COMP360 in mental health care, post the recent COMP360 data in treatment-resistant depression. Over 300M people worldwide live with depression and, of the...
Demonstrates atai’s confidence in COMPASS’ Phase 2b data and its potential for patients with treatment-resistant depression Reinforces COMPASS as highly complementary to atai’s diversified approach to innovation in mental health NEW YORK, Nov. 29, 2021...
The obesity epidemic is still bursting at the seams. In fact, according to Medical News Today, the issue contributes to more than five million global deaths every year. In addition, a ccording to the World Health Organization, obesity has tripled since 1975. More than 1.9 billion adults...
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and t...
Atai Life Sciences N.V. (ATAI) Q3 2021 Earnings Conference Call November 15, 2021, 08:30 AM ET Company Participants Chad Messer - VP, IR, Strategic Finance Florian Brand - CEO Srinivas Rao - Co-Founder & Chief Scientific Officer Greg Weaver - CFO Conference Call Participants Charles Dunca...
ATAI Life Sciences (NASDAQ:ATAI): Q3 GAAP EPS of -$0.21 beats by $0.02. Revenue of $0.27M Press Release Cash and cash equivalents totaled $430.3M as of September 30, 2021, compared to $97.2M as of December 31, 2020. For further details see: ATAI Life Sciences EPS beats by $0.02
-Positive topline results from COMP360’s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...